PulseAugur / Brief
EN
LIVE 13:51:35

Brief

last 24h
[2/2] 224 sources

Multi-source AI news clustered, deduplicated, and scored 0–100 across authority, cluster strength, headline signal, and time decay.

  1. TOOL · 36氪 (36Kr) 中文(ZH) ·

    Huiyu Pharmaceutical: Clinical Trial Application for Injectable HY07121 (Subcutaneous Injection) Accepted

    Huayu Pharmaceutical's subsidiary, Huayu Haiyue, has received approval from China's National Medical Products Administration to begin clinical trials for HY07121, a novel subcutaneous injection for advanced solid tumors. This innovative biologic is a triple-target fusion protein designed to combat PD-1, TIGIT, and IL-15/IL-15Rα, aiming to enhance patient convenience and reduce side effects. Currently, no other triple-target products are available on the market. AI

    IMPACT This development signifies progress in targeted cancer therapies, potentially offering new treatment options with improved patient outcomes.

  2. TOOL · 36氪 (36Kr) 中文(ZH) ·

    Jiangshan Oupai: Appoints Chen Chunjin as Secretary of the Board of Directors

    Jiangshan Oupai has appointed Chen Chunjin as the company's board secretary, effective immediately. This move means the company's chairman, Wu Shuigen, will no longer perform the duties of the board secretary. Separately, Huiyu Pharmaceutical's subsidiary, Huiyu Haiyue, has received acceptance from the National Medical Products Administration for its clinical trial application for subcutaneous injection HY07121, a novel biological product designed to treat advanced solid tumors by targeting PD-1, TIGIT, and IL-15/IL-15Rα. AI